PW Medtech Group Limited (01358) disclosed that as of February 2, 2026, the total number of issued ordinary shares stood at 1,473,589,098, unchanged since January 30, 2026. However, between September 23, 2025, and February 2, 2026, the company repurchased a series of its shares for cancellation, with the latest repurchase involving 410,000 shares at HKD1.28 per share on February 2, 2026.

According to the disclosure, the aggregation of repurchases during this period has not yet affected the issued share total, as these shares remain “repurchased for cancellation but not yet cancelled.” Under the repurchase mandate approved on June 10, 2025, PW Medtech is authorized to repurchase up to 148,673,509 shares, and the total number repurchased so far stands at 16,278,000 shares, representing approximately 1.0949% of the number of issued shares as at the date of that mandate.

The company’s repurchases have been conducted at prices ranging from HKD1.28 to HKD1.555 since September 2025. The overall figure includes smaller transactions in late January 2026 as well as the 410,000 shares repurchased on February 2, 2026, for a total consideration of HKD524,800.